NCT06809140 2026-02-23
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Recruiting
Hoosier Cancer Research Network
The University of Hong Kong